CRISPR Therapeutics AG (CRSP) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
CRISPR Therapeutics’s revenue went from $5M in fiscal 2016 to $4M in fiscal 2025, a decline of about 4.2% a year.
Net income in fiscal 2025 was -$582M, a net margin of -16569.8%; the best year in this period was 2021 with $378M.
Over the twelve months to September 30, 2026, revenue was $25M and net income -$456M.
Free cash flow was -$346M in fiscal 2025 and positive in 2 of the 10 years shown.
The diluted share count rose 634% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $4M | $37M | $371M | $1M | $915M | $719000 | $290M | $3M | $41M | $5M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$532M | -$665M | -$467M | -$223M | -$673M | $374M | -$354M | $47M | -$159M | -$65M | -$68M |
| Net income | -$456M | -$582M | -$366M | -$154M | -$650M | $378M | -$349M | $67M | -$165M | -$68M | -$23M |
| EPS (diluted) | $-4.72 | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-1.89 |
| R&D | $291M | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M |
| Revenue growth | — | −90.6% | −90.0% | +30885.5% | −99.9% | +127200.0% | −99.8% | +9169.9% | −92.4% | +693.9% | +1990.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$375M | -$345M | -$143M | -$260M | -$496M | $539M | -$238M | $57M | -$96M | -$70M | -$53M |
| Capital spending | -$2M | -$914000 | -$2M | -$9M | -$37M | -$82M | -$18M | -$7M | -$3M | -$8M | -$3M |
| Free cash flow | -$377M | -$346M | -$145M | -$270M | -$533M | $457M | -$257M | $50M | -$99M | -$78M | -$56M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | $57000 | — | — |
| Stock-based pay | $70M | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $2.0B | $1.9B | $1.7B | $1.8B | $2.4B | $1.7B | $944M | $457M | $240M | $316M |
| Debt | — | $207M | $224M | $239M | $244M | $225M | $61M | $53M | $0 | $0 | $0 |
| Equity | — | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B | $1.7B | $939M | $392M | $188M | $233M |
| Total assets | — | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B | $1.8B | $1.1B | $489M | $271M | $345M |
| Shares (diluted) | 97M | 90M | 84M | 79M | 78M | 80M | 66M | 57M | 48M | 40M | 12M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -2114.8% | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% |
| Net margin | -1812.1% | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% |
| FCF margin | -1496.6% | -9855.5% | -387.7% | -72.7% | -44484.9% | 50.0% | -35705.7% | 17.3% | -3169.4% | -190.0% | -1082.0% |
| ROIC | — | -24.7% | -17.1% | -8.3% | -31.7% | 14.2% | -16.2% | 4.7% | -32.0% | -27.2% | -23.1% |
| ROE | — | -30.3% | -19.0% | -8.2% | -34.7% | 15.7% | -21.0% | 7.1% | -42.1% | -36.4% | -10.0% |
Frequently asked questions
What is CRISPR Therapeutics’s annual revenue?
$4M in fiscal 2025 and $25M over the twelve months to September 30, 2026.
How much profit does CRISPR Therapeutics make?
Net income was -$582M in fiscal 2025 (net margin -16569.8%).
Is CRISPR Therapeutics’s revenue growing?
No: revenue fell 90.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.